Alanine transferase levels (ALT) and triglyceride-glucose index are risk factors for type 2 diabetes mellitus in obese patients.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE

Publication: Berlin : Springer Verlag
Original Publication: Berlin : Springer International, c1991-

Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/epidemiology ; Metabolic Syndrome*/complications ; Metabolic Syndrome*/epidemiology; Male ; Humans ; Female ; Triglycerides ; Glucose ; Transferases ; Risk Factors ; Obesity/complications ; Body Mass Index ; Alanine Transaminase ; Alanine

Aims: The role of liver steatosis and increased liver enzymes (ALT) in increasing incident type 2 diabetes mellitus (T2DM) is debated, because of their differential effects on different ethnicities and populations. The aim of this study was to evaluate the role of elevated ALT in the development of T2DM in non-diabetic obese subjects receiving routine medical treatment.
Methods: A total of 1005 subjects [296 men and 709 women, aged 45.7 ± 13.12 years, body mass index (BMI) 39.5 ± 4.86 kg/m ² ] were followed for a mean period of 14.3 ± 4.44 years. Subjects were evaluated for several metabolic variables, including the triglyceride-glucose index and the presence of metabolic syndrome (IDF 2005 definition), and were subdivided into ALT quartiles.
Results: T2DM developed in 136 subjects, and the difference was significant between the first and the fourth ALT quartile (p = 0.048). Both at univariate analysis and at stepwise regression, ALT quartiles were associated with incident T2DM. Traditional risk factors for T2DM coexisted, with a somehow greater predictive value, such as triglyceride-glucose index, age, arterial hypertension, LDL-cholesterol, and metabolic syndrome.
Conclusions: These data suggest an association between elevated ALT levels and the risk of incident T2DM in obesity.
(© 2023. The Author(s).)

Diabetes. 2005 Nov;54(11):3140-7. (PMID: 16249437)
BMJ Open. 2023 Aug 7;13(8):e074007. (PMID: 37550028)
Acta Diabetol. 2020 Mar;57(3):323-333. (PMID: 31598798)
Hepatology. 2024 Mar 1;79(3):E93-E94. (PMID: 37983810)
Diabetes. 2004 Nov;53(11):2855-60. (PMID: 15504965)
J Clin Invest. 1997 Nov 1;100(9):2158-69. (PMID: 9410892)
Dig Liver Dis. 2024 Jan;56(1):144-151. (PMID: 37507284)
Cardiovasc Diabetol. 2020 Jan 15;19(1):8. (PMID: 31941513)
Cardiovasc Diabetol. 2018 Dec 29;17(1):161. (PMID: 30594184)
Cardiovasc Diabetol. 2023 Aug 26;22(1):226. (PMID: 37633936)
Biomedicines. 2023 Jul 27;11(8):. (PMID: 37626617)
Obes Surg. 2009 Jan;19(1):80-6. (PMID: 18820980)
Diabetes Care. 2005 Dec;28(12):2913-8. (PMID: 16306554)
Front Endocrinol (Lausanne). 2022 Oct 13;13:961762. (PMID: 36313767)
J Hepatol. 2020 Jul;73(1):202-209. (PMID: 32278004)
Curr Med Res Opin. 2005 Aug;21(8):1157-9. (PMID: 16083523)
Nutr Metab Cardiovasc Dis. 2009 Mar;19(3):198-204. (PMID: 18684601)
Diabetes Care. 2014 Aug;37(8):2225-32. (PMID: 24969582)
Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12490-5. (PMID: 8901609)
Acta Diabetol. 2014;51(3):361-8. (PMID: 24085682)
Sci Rep. 2022 Jun 25;12(1):10819. (PMID: 35752681)
Diabetes. 1988 Dec;37(12):1595-607. (PMID: 3056758)
Ann Hepatol. 2012 Nov-Dec;11(6):966. (PMID: 23109465)

Keywords: Liver; Metabolic syndrome; Triglyceride-glucose index; Type 2 diabetes

0 (Triglycerides)
IY9XDZ35W2 (Glucose)
EC 2.- (Transferases)
EC 2.6.1.2 (Alanine Transaminase)
OF5P57N2ZX (Alanine)

Date Created: 20231206 Date Completed: 20240327 Latest Revision: 20240328

20240329

PMC10963574

10.1007/s00592-023-02209-6

38057389